- Home
- SGN vs SCNI Comparison
SGN vs SCNI Comparison
Compare SGN & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGN | SCNI |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | Israel |
| Employees | 9 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGN | SCNI |
|---|---|---|
| Price | $0.17 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 29.7M | 46.0K |
| Earning Date | 11-12-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $366,344.00 | ★ $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.79 |
| Revenue Growth | N/A | ★ 303.87 |
| 52 Week Low | $0.11 | $0.61 |
| 52 Week High | $7.24 | $6.18 |
Technical Indicators
Market Signals| Indicator | SGN | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 24.45 | 60.15 |
| Support Level | $0.11 | $0.78 |
| Resistance Level | $0.19 | $0.96 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 9.56 | 90.33 |
Price Performance
Historical ComparisonAbout SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.